Cellular therapies in systemic lupus erythematosus: recent progress and future directions

Area of Science:

• Immunology
• Rheumatology
• Cellular Therapy

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease causing chronic inflammation and organ damage.
• Many patients with severe or relapsing SLE do not respond to current treatments, leading to irreversible damage.
• CAR T-cell therapy is emerging as a novel approach for refractory autoimmune diseases.

Purpose of the Study:

• To review the rationale and evidence for using CAR T-cell therapy in SLE.
• To discuss the potential of CAR T-cell therapy to induce deep and sustained remission.
• To explore challenges and future directions for CAR T-cell therapy in SLE.

Main Methods:

• Review of preclinical and clinical data on CAR T-cell therapy for SLE.
• Focus on CD19-directed CAR T-cell therapy targeting B-cells.
• Analysis of immunopathogenic mechanisms and therapeutic potential.

Main Results:

• CAR T-cell therapy demonstrates potential for deep B-cell depletion and sustained remission in refractory SLE.
• CD19-directed CAR T-cell therapy has shown promising results in early clinical studies.
• This approach may fundamentally reset autoimmune responses, offering a disease-modifying strategy.

Conclusions:

• CAR T-cell therapy represents a transformative strategy for managing refractory SLE.
• Further research and well-designed trials are needed to optimize safety, efficacy, and long-term outcomes.
• Targeting specific B-cell subsets with advanced CAR constructs may enhance therapeutic benefits.